Alumis Inc (ALMS)

$27.04 +0.62 (2.35%)
Market Cap 2.56B
Revenue (ttm) 0.00
Net Income (ttm) -294.23M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 889,800
Avg Vol 3,321,316
Day's Range N/A - N/A
Shares Out 104.39M
Stochastic %K 74%
Beta -2.09
Analysts Strong Sell
Price Target $37.25

Company Profile

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company's clinical asset comprises ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. It also develops interferon regulatory factor 5 (IRF5) to ad...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 231 6625
Address:
280 East Grand Avenue, South San Francisco, United States
ParagonStar1
ParagonStar1 Feb. 3 at 12:08 PM
$ALMS Strong Phase 3 Clinical Results..
0 · Reply
ParagonStar1
ParagonStar1 Feb. 3 at 12:05 PM
$ALMS
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 2 at 7:04 PM
$ALMS RSI: 65.20, MACD: 3.6377 Vol: 4.80, MA20: 22.86, MA50: 14.95 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
aletz
aletz Jan. 30 at 1:08 PM
$ALMS February Wk1 AI Scanner https://www.biostockinfo.com/biotech-catalyst-ai-scanner-february-wk1/
0 · Reply
Bullymebearishyou
Bullymebearishyou Jan. 29 at 8:11 PM
$CATX Was hoping for a $ALMS run
0 · Reply
teksviler
teksviler Jan. 29 at 4:42 PM
$ALMS $LFLR.CSE $BE $IBM RKLB.. $$$$
0 · Reply
Sharpeetrades
Sharpeetrades Jan. 29 at 12:34 PM
$ALMS i love how u der the radar this stock is and just keep quietly climbing
0 · Reply
outlawinvestor1
outlawinvestor1 Jan. 28 at 8:46 PM
$ALMS still worth at least $6B. current mc is $3.5b.
0 · Reply
Jonita
Jonita Jan. 28 at 8:33 PM
$ALMS 💪🏻💪🏻💪🏻💪🏻
0 · Reply
droog_botski
droog_botski Jan. 28 at 8:08 PM
$ALMS Short squeeze or what gives ? 1-15 short interest was 8,672,088 according to NASDAQ
1 · Reply
Latest News on ALMS
Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Jan 9, 2026, 4:05 PM EST - 25 days ago

Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Alumis Announces Pricing of Upsized Public Offering of Common Stock

Jan 7, 2026, 10:52 PM EST - 27 days ago

Alumis Announces Pricing of Upsized Public Offering of Common Stock

Alumis Up On Phase 3 Envudeucitinib Success: Oral Psoriasis Therapy Shows Promise

Jan 7, 2026, 11:22 AM EST - 27 days ago

Alumis Up On Phase 3 Envudeucitinib Success: Oral Psoriasis Therapy Shows Promise

Alumis Announces Proposed Public Offering of Common Stock

Jan 6, 2026, 4:12 PM EST - 4 weeks ago

Alumis Announces Proposed Public Offering of Common Stock

Alumis Skin Drug Shows Clear Benefits In Late Trials, Stock Soars

Jan 6, 2026, 10:47 AM EST - 4 weeks ago

Alumis Skin Drug Shows Clear Benefits In Late Trials, Stock Soars

Alumis skin disease drug meets main goal of two late-stage trials

Jan 6, 2026, 7:07 AM EST - 4 weeks ago

Alumis skin disease drug meets main goal of two late-stage trials

Alumis' Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program

Jan 6, 2026, 7:00 AM EST - 4 weeks ago

Alumis' Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program

Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis

Jan 5, 2026, 5:00 PM EST - 4 weeks ago

Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis

Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Nov 13, 2025, 4:15 PM EST - 2 months ago

Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Alumis to Participate in Upcoming November Investor Conferences

Nov 4, 2025, 8:00 AM EST - 3 months ago

Alumis to Participate in Upcoming November Investor Conferences

Alumis Inc. (ALMS) Presents at Stifel Virtual Immunology and Inflammation Forum Transcript

Sep 17, 2025, 4:53 AM EDT - 4 months ago

Alumis Inc. (ALMS) Presents at Stifel Virtual Immunology and Inflammation Forum Transcript

Alumis to Participate in Upcoming September Investor Conferences

Aug 29, 2025, 7:00 AM EDT - 5 months ago

Alumis to Participate in Upcoming September Investor Conferences

Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 13, 2025, 4:05 PM EDT - 6 months ago

Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus

Jul 24, 2025, 7:30 AM EDT - 6 months ago

Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus

Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary

Jul 14, 2025, 4:05 PM EDT - 7 months ago

Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary

Alumis to Present at the Jefferies Global Healthcare Investor Conference

May 29, 2025, 4:15 PM EDT - 8 months ago

Alumis to Present at the Jefferies Global Healthcare Investor Conference

Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis

May 29, 2025, 7:55 AM EDT - 8 months ago

Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis

Alumis Completes Merger with ACELYRIN

May 21, 2025, 9:10 AM EDT - 9 months ago

Alumis Completes Merger with ACELYRIN

Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements

May 14, 2025, 4:05 PM EDT - 9 months ago

Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements

Alumis Stockholders Approve Merger with ACELYRIN

May 13, 2025, 1:00 PM EDT - 9 months ago

Alumis Stockholders Approve Merger with ACELYRIN

Alumis and ACELYRIN Announce Amended Merger Agreement

Apr 21, 2025, 6:30 AM EDT - 10 months ago

Alumis and ACELYRIN Announce Amended Merger Agreement

ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN

Apr 16, 2025, 5:31 PM EDT - 10 months ago

ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN

SLRN

Hyatt Hotels, THOR Industries And Other Big Stocks Moving Lower On Monday

Apr 14, 2025, 10:02 AM EDT - 10 months ago

Hyatt Hotels, THOR Industries And Other Big Stocks Moving Lower On Monday

H THO AMRN CCO ECX HZO NUTX

Top 3 Health Care Stocks That May Crash In Q2

Apr 7, 2025, 11:23 AM EDT - 10 months ago

Top 3 Health Care Stocks That May Crash In Q2

CMRX DERM

Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger

Apr 4, 2025, 4:34 PM EDT - 10 months ago

Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger

Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan

Mar 25, 2025, 2:30 AM EDT - 11 months ago

Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan

Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements

Mar 19, 2025, 4:05 PM EDT - 11 months ago

Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements

Alumis to Present at Leerink's 2025 Global Healthcare Conference

Mar 10, 2025, 8:00 AM EDT - 11 months ago

Alumis to Present at Leerink's 2025 Global Healthcare Conference

Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

Mar 8, 2025, 9:00 AM EST - 11 months ago

Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger

Mar 4, 2025, 9:01 AM EST - 1 year ago

Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger

ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger

Mar 4, 2025, 9:00 AM EST - 1 year ago

ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger

SLRN

Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout

Feb 28, 2025, 9:08 AM EST - 1 year ago

Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout

Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases

Feb 27, 2025, 4:15 PM EST - 1 year ago

Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases

Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 10, 2025, 4:45 PM EST - 1 year ago

Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ACELYRIN, INC.

Feb 7, 2025, 3:22 PM EST - 1 year ago

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ACELYRIN, INC.

SLRN

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

Feb 6, 2025, 4:15 PM EST - 1 year ago

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

Alumis Strengthens Leadership Team with Key Appointments

Jan 28, 2025, 8:00 AM EST - 1 year ago

Alumis Strengthens Leadership Team with Key Appointments

Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements

Nov 13, 2024, 4:05 PM EST - 1 year ago

Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside

Oct 17, 2024, 2:32 PM EDT - 1 year ago

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside

BMY

Alumis: Could This Broken Immunology IPO Become The Next Amgen?

Oct 4, 2024, 2:00 AM EDT - 1 year ago

Alumis: Could This Broken Immunology IPO Become The Next Amgen?

Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study

Sep 27, 2024, 9:00 AM EDT - 1 year ago

Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study

Alumis: Recent IPO With Differentiated Data In Autoimmune Diseases

Sep 16, 2024, 4:32 PM EDT - 1 year ago

Alumis: Recent IPO With Differentiated Data In Autoimmune Diseases

Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements

Aug 13, 2024, 4:05 PM EDT - 1 year ago

Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements

Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis

Jul 29, 2024, 8:00 AM EDT - 1 year ago

Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis

Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation

Jul 24, 2024, 3:18 PM EDT - 1 year ago

Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation

U.S. IPO Weekly Recap: 2Q IPO Market Closes Out With Sizable Pricings And Pipeline Additions

Jul 1, 2024, 11:51 AM EDT - 1 year ago

U.S. IPO Weekly Recap: 2Q IPO Market Closes Out With Sizable Pricings And Pipeline Additions

AGH INHI LB LINE TBN TWFG WBTN

Immune Disease-Focused Alumis Raises $250M In Downsized Initial Public Offering

Jun 28, 2024, 1:36 PM EDT - 1 year ago

Immune Disease-Focused Alumis Raises $250M In Downsized Initial Public Offering

Biopharma firm Alumis' shares fall nearly 16% in Nasdaq debut

Jun 28, 2024, 12:58 PM EDT - 1 year ago

Biopharma firm Alumis' shares fall nearly 16% in Nasdaq debut

Therapy developer Alumis prices U.S. IPO at about $902 mln valuation

Jun 28, 2024, 12:43 AM EDT - 1 year ago

Therapy developer Alumis prices U.S. IPO at about $902 mln valuation

ParagonStar1
ParagonStar1 Feb. 3 at 12:08 PM
$ALMS Strong Phase 3 Clinical Results..
0 · Reply
ParagonStar1
ParagonStar1 Feb. 3 at 12:05 PM
$ALMS
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 2 at 7:04 PM
$ALMS RSI: 65.20, MACD: 3.6377 Vol: 4.80, MA20: 22.86, MA50: 14.95 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
aletz
aletz Jan. 30 at 1:08 PM
$ALMS February Wk1 AI Scanner https://www.biostockinfo.com/biotech-catalyst-ai-scanner-february-wk1/
0 · Reply
Bullymebearishyou
Bullymebearishyou Jan. 29 at 8:11 PM
$CATX Was hoping for a $ALMS run
0 · Reply
teksviler
teksviler Jan. 29 at 4:42 PM
$ALMS $LFLR.CSE $BE $IBM RKLB.. $$$$
0 · Reply
Sharpeetrades
Sharpeetrades Jan. 29 at 12:34 PM
$ALMS i love how u der the radar this stock is and just keep quietly climbing
0 · Reply
outlawinvestor1
outlawinvestor1 Jan. 28 at 8:46 PM
$ALMS still worth at least $6B. current mc is $3.5b.
0 · Reply
Jonita
Jonita Jan. 28 at 8:33 PM
$ALMS 💪🏻💪🏻💪🏻💪🏻
0 · Reply
droog_botski
droog_botski Jan. 28 at 8:08 PM
$ALMS Short squeeze or what gives ? 1-15 short interest was 8,672,088 according to NASDAQ
1 · Reply
Quantumup
Quantumup Jan. 27 at 12:39 PM
JPMorgan reiterated $PTGX Overweight; $93 and said, With shares pulling back from all-time highs in mid-Dec (-14% since Dec 12th), we wanted to re-evaluate the key levers in the story and discuss the set-up for the remainder of the year. $JNJ $ABVX $ALMS LLY ABBV PFE $TAK JPMorgan went on to say: https://x.com/Quantumup1/status/2016126900440043740?s=20
0 · Reply
kshonstocks
kshonstocks Jan. 26 at 4:15 PM
$ALMS has shorts, keep an eye; $ALMS Short Interest Ratio (Days To Cover) 1.9 https://shortsqueeze.com/?symbol=alms
0 · Reply
10xby3
10xby3 Jan. 26 at 2:47 PM
$MRNA bought the dip here and also for $ALMS - happy hunting!
0 · Reply
10xby3
10xby3 Jan. 26 at 9:01 AM
$ALMS load all u can - we run higher green to 30 in a sea of red this week! 5billion cap for buyout is what i see - 40 per share, so may be we get to 30 very soon before announced. The data r so good and clean! And why are the management so quiet - because they r working the deal points now! if u bought in the offering u make 150% in a month. not bad…
0 · Reply
ChartHawwwwk
ChartHawwwwk Jan. 24 at 8:20 PM
$SVRE 0 short and massive bids... on a 900k float... Next 500% runner like $SMX $ROLR $HYMC $ALMS ?
1 · Reply
Roundesk_C
Roundesk_C Jan. 24 at 2:56 AM
$ALMS this ticker seems to have potential to go higher. despite of 2 successful phase 3 readout and sufficient cash runways, still not knowing their future development. can someone share your insight about its possible development and valuation model? appreciated.
0 · Reply
Afisyanadoh
Afisyanadoh Jan. 23 at 6:25 PM
$ALMS What the devil? I thought this ticker only went up???
1 · Reply
Poester
Poester Jan. 23 at 1:33 PM
$ALMS I agree with a possible buyout. One thing we're waiting on is a smart giant that will purchase while the stock price is still in the mid 20's.
0 · Reply
RunnerSignals
RunnerSignals Jan. 22 at 9:54 PM
$ALB $ALMS $AMZE $ANF $AQST upgrades spark interest. traders are eyeing growth stories with real upside https://stocksrunner.com/news/2026-01-22-stock-upgrades-today
0 · Reply
buylocellhi
buylocellhi Jan. 22 at 8:09 PM
$ALMS imo this one will be bought out eventually,, who knows, could happen sooner than we think.
1 · Reply
buylocellhi
buylocellhi Jan. 22 at 8:05 PM
$ALMS a $27 > will prove my point
0 · Reply
buylocellhi
buylocellhi Jan. 22 at 8:03 PM
$ALMS today was a “collection day” of shares from weak hands. I am expecting a real good tomorrow!
0 · Reply